Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:51 UTC |
---|
HMDB ID | HMDB0015063 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Azacitidine |
---|
Description | Azacitidine is only found in individuals that have used or taken this drug. It is a pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent. [PubChem]Azacitidine (5-azacytidine) is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death. As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein. Its incorporation into DNA leads to a covalent binding with DNA methyltransferases, which prevents DNA synthesis and subsequent cytotoxicity. |
---|
Structure | NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1 |
---|
Synonyms | Value | Source |
---|
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one | ChEBI | Azacitidina | ChEBI | Azacitidinum | ChEBI | Vidaza | Kegg | 4-Amino-1-b-D-ribofuranosyl-S-triazin-2(1H)-one | Generator | 4-Amino-1-β-D-ribofuranosyl-S-triazin-2(1H)-one | Generator | 5 AZC | HMDB | Azacytidine | HMDB | Pharmion brand OF azacitidine | HMDB | 5 Azacytidine | HMDB | Azacitidine | ChEBI |
|
---|
Chemical Formula | C8H12N4O5 |
---|
Average Molecular Weight | 244.2047 |
---|
Monoisotopic Molecular Weight | 244.080769514 |
---|
IUPAC Name | 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one |
---|
Traditional Name | azacitidine |
---|
CAS Registry Number | 320-67-2 |
---|
SMILES | NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O |
---|
InChI Identifier | InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1 |
---|
InChI Key | NMUSYJAQQFHJEW-KVTDHHQDSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as glycosylamines. Glycosylamines are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether). |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic oxygen compounds |
---|
Class | Organooxygen compounds |
---|
Sub Class | Carbohydrates and carbohydrate conjugates |
---|
Direct Parent | Glycosylamines |
---|
Alternative Parents | |
---|
Substituents | - N-glycosyl compound
- Pentose monosaccharide
- Amino-1,3,5-triazine
- Aminotriazine
- Triazinone
- Monosaccharide
- Triazine
- 1,3,5-triazine
- Heteroaromatic compound
- Tetrahydrofuran
- Secondary alcohol
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Amine
- Primary amine
- Primary alcohol
- Alcohol
- Organonitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic nitrogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 229 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 12.1 g/L | Not Available | LogP | -3.5 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Azacitidine,1TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)[C@H](O)[C@@H]1O | 2464.8 | Semi standard non polar | 33892256 | Azacitidine,1TMS,isomer #2 | C[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N)=NC2=O)[C@@H]1O | 2458.3 | Semi standard non polar | 33892256 | Azacitidine,1TMS,isomer #3 | C[Si](C)(C)O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C=NC(N)=NC1=O | 2450.4 | Semi standard non polar | 33892256 | Azacitidine,1TMS,isomer #4 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C=N1 | 2500.8 | Semi standard non polar | 33892256 | Azacitidine,2TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)[C@H](O[Si](C)(C)C)[C@@H]1O | 2383.4 | Semi standard non polar | 33892256 | Azacitidine,2TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)[C@H](O)[C@@H]1O[Si](C)(C)C | 2379.6 | Semi standard non polar | 33892256 | Azacitidine,2TMS,isomer #3 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C)[C@@H](O)[C@H]2O)C=N1 | 2431.0 | Semi standard non polar | 33892256 | Azacitidine,2TMS,isomer #4 | C[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N)=NC2=O)[C@@H]1O[Si](C)(C)C | 2361.5 | Semi standard non polar | 33892256 | Azacitidine,2TMS,isomer #5 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O[Si](C)(C)C)[C@H]2O)C=N1 | 2443.2 | Semi standard non polar | 33892256 | Azacitidine,2TMS,isomer #6 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O[Si](C)(C)C)C=N1 | 2435.2 | Semi standard non polar | 33892256 | Azacitidine,2TMS,isomer #7 | C[Si](C)(C)N(C1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C=N1)[Si](C)(C)C | 2427.3 | Semi standard non polar | 33892256 | Azacitidine,3TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)[C@H](O[Si](C)(C)C)[C@@H]1O[Si](C)(C)C | 2310.3 | Semi standard non polar | 33892256 | Azacitidine,3TMS,isomer #2 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C)[C@@H](O)[C@H]2O[Si](C)(C)C)C=N1 | 2409.9 | Semi standard non polar | 33892256 | Azacitidine,3TMS,isomer #3 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H]2O)C=N1 | 2405.8 | Semi standard non polar | 33892256 | Azacitidine,3TMS,isomer #4 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@H](O)[C@@H]1O | 2409.3 | Semi standard non polar | 33892256 | Azacitidine,3TMS,isomer #5 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O[Si](C)(C)C)[C@H]2O[Si](C)(C)C)C=N1 | 2401.8 | Semi standard non polar | 33892256 | Azacitidine,3TMS,isomer #6 | C[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@@H]1O | 2400.3 | Semi standard non polar | 33892256 | Azacitidine,3TMS,isomer #7 | C[Si](C)(C)O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC1=O | 2395.1 | Semi standard non polar | 33892256 | Azacitidine,4TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H]2O[Si](C)(C)C)C=N1 | 2420.8 | Semi standard non polar | 33892256 | Azacitidine,4TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H]2O[Si](C)(C)C)C=N1 | 2545.8 | Standard non polar | 33892256 | Azacitidine,4TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H]2O[Si](C)(C)C)C=N1 | 3284.6 | Standard polar | 33892256 | Azacitidine,4TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C)[C@@H]1O | 2432.9 | Semi standard non polar | 33892256 | Azacitidine,4TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C)[C@@H]1O | 2560.6 | Standard non polar | 33892256 | Azacitidine,4TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C)[C@@H]1O | 3062.0 | Standard polar | 33892256 | Azacitidine,4TMS,isomer #3 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@H](O)[C@@H]1O[Si](C)(C)C | 2422.2 | Semi standard non polar | 33892256 | Azacitidine,4TMS,isomer #3 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@H](O)[C@@H]1O[Si](C)(C)C | 2544.1 | Standard non polar | 33892256 | Azacitidine,4TMS,isomer #3 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@H](O)[C@@H]1O[Si](C)(C)C | 3019.2 | Standard polar | 33892256 | Azacitidine,4TMS,isomer #4 | C[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@@H]1O[Si](C)(C)C | 2420.3 | Semi standard non polar | 33892256 | Azacitidine,4TMS,isomer #4 | C[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@@H]1O[Si](C)(C)C | 2561.4 | Standard non polar | 33892256 | Azacitidine,4TMS,isomer #4 | C[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@@H]1O[Si](C)(C)C | 2991.6 | Standard polar | 33892256 | Azacitidine,5TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C)[C@@H]1O[Si](C)(C)C | 2471.4 | Semi standard non polar | 33892256 | Azacitidine,5TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C)[C@@H]1O[Si](C)(C)C | 2551.3 | Standard non polar | 33892256 | Azacitidine,5TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C)[C@@H]1O[Si](C)(C)C | 2819.9 | Standard polar | 33892256 | Azacitidine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)[C@H](O)[C@@H]1O | 2702.5 | Semi standard non polar | 33892256 | Azacitidine,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N)=NC2=O)[C@@H]1O | 2701.2 | Semi standard non polar | 33892256 | Azacitidine,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C=NC(N)=NC1=O | 2690.5 | Semi standard non polar | 33892256 | Azacitidine,1TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C=N1 | 2719.9 | Semi standard non polar | 33892256 | Azacitidine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O | 2837.8 | Semi standard non polar | 33892256 | Azacitidine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)[C@H](O)[C@@H]1O[Si](C)(C)C(C)(C)C | 2835.2 | Semi standard non polar | 33892256 | Azacitidine,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H]2O)C=N1 | 2877.2 | Semi standard non polar | 33892256 | Azacitidine,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N)=NC2=O)[C@@H]1O[Si](C)(C)C(C)(C)C | 2806.8 | Semi standard non polar | 33892256 | Azacitidine,2TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O)C=N1 | 2866.9 | Semi standard non polar | 33892256 | Azacitidine,2TBDMS,isomer #6 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O[Si](C)(C)C(C)(C)C)C=N1 | 2850.9 | Semi standard non polar | 33892256 | Azacitidine,2TBDMS,isomer #7 | CC(C)(C)[Si](C)(C)N(C1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C=N1)[Si](C)(C)C(C)(C)C | 2869.6 | Semi standard non polar | 33892256 | Azacitidine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N)=NC2=O)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C | 3014.4 | Semi standard non polar | 33892256 | Azacitidine,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H]2O[Si](C)(C)C(C)(C)C)C=N1 | 3064.5 | Semi standard non polar | 33892256 | Azacitidine,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O)C=N1 | 3059.1 | Semi standard non polar | 33892256 | Azacitidine,3TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@H](O)[C@@H]1O | 3039.2 | Semi standard non polar | 33892256 | Azacitidine,3TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O[Si](C)(C)C(C)(C)C)C=N1 | 3046.3 | Semi standard non polar | 33892256 | Azacitidine,3TBDMS,isomer #6 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@@H]1O | 3053.5 | Semi standard non polar | 33892256 | Azacitidine,3TBDMS,isomer #7 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC1=O | 3038.2 | Semi standard non polar | 33892256 | Azacitidine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O[Si](C)(C)C(C)(C)C)C=N1 | 3224.0 | Semi standard non polar | 33892256 | Azacitidine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O[Si](C)(C)C(C)(C)C)C=N1 | 3310.6 | Standard non polar | 33892256 | Azacitidine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]2O[Si](C)(C)C(C)(C)C)C=N1 | 3523.2 | Standard polar | 33892256 | Azacitidine,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O | 3249.2 | Semi standard non polar | 33892256 | Azacitidine,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O | 3352.7 | Standard non polar | 33892256 | Azacitidine,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O | 3338.7 | Standard polar | 33892256 | Azacitidine,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@H](O)[C@@H]1O[Si](C)(C)C(C)(C)C | 3237.2 | Semi standard non polar | 33892256 | Azacitidine,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@H](O)[C@@H]1O[Si](C)(C)C(C)(C)C | 3335.5 | Standard non polar | 33892256 | Azacitidine,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@H](O)[C@@H]1O[Si](C)(C)C(C)(C)C | 3306.1 | Standard polar | 33892256 | Azacitidine,4TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@@H]1O[Si](C)(C)C(C)(C)C | 3240.2 | Semi standard non polar | 33892256 | Azacitidine,4TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@@H]1O[Si](C)(C)C(C)(C)C | 3342.2 | Standard non polar | 33892256 | Azacitidine,4TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@@H]1O[Si](C)(C)C(C)(C)C | 3285.6 | Standard polar | 33892256 | Azacitidine,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C | 3423.9 | Semi standard non polar | 33892256 | Azacitidine,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C | 3457.6 | Standard non polar | 33892256 | Azacitidine,5TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C | 3241.3 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Azacitidine GC-MS (Non-derivatized) - 70eV, Positive | splash10-08nc-9420000000-deb4c3c2e01ce611d805 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Azacitidine GC-MS (3 TMS) - 70eV, Positive | splash10-0072-9783700000-4e1593dee5d4eee4fa53 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Azacitidine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 10V, Positive-QTOF | splash10-03di-0910000000-bf3b4f701f0a4e9f2cd8 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 20V, Positive-QTOF | splash10-03di-6900000000-5d329d9eaea6433ed7cb | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 40V, Positive-QTOF | splash10-03dm-9300000000-9df054033868819ef47c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 10V, Negative-QTOF | splash10-0udl-4690000000-2cfa5eaefe0d852fc770 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 20V, Negative-QTOF | splash10-01ox-9600000000-c47176436749bbaa6201 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 40V, Negative-QTOF | splash10-00l6-9100000000-71ffe7618fd437f42131 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 10V, Positive-QTOF | splash10-03di-0900000000-ad27e26e064f360f3006 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 20V, Positive-QTOF | splash10-03di-4900000000-5d9421c40d3f45d9dc69 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 40V, Positive-QTOF | splash10-03ka-9500000000-79a738f312e868981bd2 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 10V, Negative-QTOF | splash10-01ox-1960000000-94c1bdd861f9dd5e7a9e | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 20V, Negative-QTOF | splash10-0006-9500000000-0f6f7a947b16f6e8119a | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Azacitidine 40V, Negative-QTOF | splash10-00kf-9000000000-6ba499348317121c0ac2 | 2021-10-11 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum |
|
---|
General References | - Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R: FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005 Mar;10(3):176-82. [PubMed:15793220 ]
- Leone G, Voso MT, Teofili L, Lubbert M: Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol. 2003 Oct;109(1):89-102. [PubMed:14585280 ]
- Ghoshal K, Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc). 2007 Jun;43(6):395-422. [PubMed:17612710 ]
- Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15;20(10):2429-40. [PubMed:12011120 ]
- Silverman LR: Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist. 2001;6 Suppl 5:8-14. [PubMed:11700387 ]
- O'Dwyer K, Maslak P: Azacitidine and the beginnings of therapeutic epigenetic modulation. Expert Opin Pharmacother. 2008 Aug;9(11):1981-6. doi: 10.1517/14656566.9.11.1981 . [PubMed:18627335 ]
- Cihak A: Biological effects of 5-azacytidine in eukaryotes. Oncology. 1974;30(5):405-22. [PubMed:4142650 ]
- Issa JP, Kantarjian H: Azacitidine. Nat Rev Drug Discov. 2005 May;Suppl:S6-7. [PubMed:15962522 ]
- Sullivan M, Hahn K, Kolesar JM: Azacitidine: a novel agent for myelodysplastic syndromes. Am J Health Syst Pharm. 2005 Aug 1;62(15):1567-73. [PubMed:16030365 ]
- Siddiqui MA, Scott LJ: Azacitidine: in myelodysplastic syndromes. Drugs. 2005;65(13):1781-9; discussion 1790-1. [PubMed:16114977 ]
- Abdulhaq H, Rossetti JM: The role of azacitidine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs. 2007 Dec;16(12):1967-75. [PubMed:18042004 ]
- Dapp MJ, Clouser CL, Patterson S, Mansky LM: 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J Virol. 2009 Nov;83(22):11950-8. doi: 10.1128/JVI.01406-09. Epub 2009 Sep 2. [PubMed:19726509 ]
- Keating GM: Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. Drugs. 2009;69(17):2501-18. doi: 10.2165/11202840-000000000-00000. [PubMed:19911860 ]
|
---|